Tempus AI stock jumped 30% after Morgan Stanley highlighted $330M-$400M in potential annual revenue gains from new diagnostic reimbursement pricing, fueling investor confidence in the company's growth trajectory.
Morgan Stanley's reimbursement-driven revenue outlook boost and management's guidance raise indicate materially higher near-term revenue for Tempus AI.
Tempus AI shares surged 30% this week following Morgan Stanley's analysis of new reimbursement pricing for its xT and xF diagnostics. CEO Eric Lefkofsky expects these updates to drive significant revenue growth, potentially exceeding the company's 25% multiyear target as data licensing bookings from major pharmaceutical partners continue to accelerate.
The rally is primarily driven by Morgan Stanley's commentary on favorable reimbursement pricing for the company's xT and xF diagnostic platforms, which is expected to provide a substantial boost to near-term revenue.